Melissa G. Lechner - Concepedia

Author

Melissa G. Lechner

Also Known As

Eric Yang, Lechner, Melissa Genevieve (author), M G Lechner, M. G. Lechner, M. Lechner, Matthew Lawlor, Melissa G Lechner, Melissa G. Lechner, Melissa Lechner, Mg Lechner

144

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

University of Southern California University of California, Los Angeles Brigham and Women's Hospital Keck Hospital of USC Dana-Farber Cancer Institute

About

Melissa G. Lechner is an author at University of Southern California specializing in medicine, immunology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	466
2	Public Health	2	2	30
3	Health Sciences	1	1	11
4	Natural Sciences	1	1	14
5	Biology	1	1	14

Melissa G. Lechner

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells Melissa G. Lechner, Daniel J. Liebertz, Alan L. Epstein The Journal of Immunology	2010	576
Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy Melissa G. Lechner, Saman S. Karimi, Keegan Barry-Holson, Journal of Immunotherapy T-regulatory CellImmunologyImmune RegulationPathologyImmunoediting	2013	360
Functional characterization of human Cd33+ And Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines Melissa G. Lechner, Carolina Megiel, Sarah M. Russell, Journal of Translational Medicine	2011	204
MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment <i>In Vitro</i> Trevor E. Angell, Melissa G. Lechner, Julie K. Jang, Clinical Cancer Research	2014	149
Clinical Features and Hospital Outcomes in Thyroid Storm: A Retrospective Cohort Study Trevor E. Angell, Melissa G. Lechner, Caroline T. Nguyen, The Journal of Clinical Endocrinology & Metabolism	2014	141
BRAF <sup>V600E</sup> in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration Trevor E. Angell, Melissa G. Lechner, Julie K. Jang, Thyroid	2014	128
Survival Signals and Targets for Therapy in Breast Implant–Associated ALK <sup>−</sup> Anaplastic Large Cell Lymphoma Melissa G. Lechner, Carolina Megiel, Connor H. Church, Clinical Cancer Research	2012	113
Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent Trevor E. Angell, Melissa G. Lechner, Alison Smith, Thyroid	2016	76
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024 John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Journal of the National Comprehensive Cancer Network	2024	74
Breast implant‐associated, ALK‐negative, T‐cell, anaplastic, large‐cell lymphoma: Establishment and characterization of a model cell line (TLBR‐1) for this newly emerging clinical entity Melissa G. Lechner, Stephen Lade, Daniel J. Liebertz, Cancer	2010	71

Page 1